Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors

Oncogene

Volumn 33, Issue 14, 2014, Pages 1872-1876

  Marino Enriquez A ^a,b   Ou, W B ^a,c   Cowley, G ^d   Luo, B ^d   Jonker, A H ^a   Mayeda, M ^a   Okamoto, M ^d   Eilers, G ^a   Czaplinski, J T ^e   Sicinska, E ^e   Wang, Y ^a   Taguchi, T ^f   Demetri, G D ^g   Root, D E ^d   Fletcher, J A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c TSINGHUA UNIVERSITY   (China)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f KOCHI UNIVERSITY   (Japan)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CDC37; Functional genomics; GIST; HSP90; shRNA library; Targeted therapy

Indexed keywords

CELASTROL; CELL CYCLE PROTEIN 37; GENOMIC RNA; HEAT SHOCK PROTEIN 90; IMATINIB; LENTIVIRUS VECTOR; MUTANT PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SHORT HAIRPIN RNA; STEM CELL FACTOR; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ESSENTIAL GENE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LIBRARY; GENE SILENCING; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GENE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHAPERONINS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LENTIVIRUS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RNA, SMALL INTERFERING; TRITERPENES;

EID: 84897983144     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.127     Document Type: Article

References (23)

1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580
2. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710
3. Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
4. DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104
5. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progressionfree survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134
6. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774
7. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190
8. Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74
9. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, DeMatteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008; 47: 853-859
10. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359
11. Antonescu CR. The GIST paradigm: Lessons for other kinase-driven cancers. J Pathol 2011; 223: 251-261
12. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66: 9153-9161
13. Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther 2012; 11: 1799-1808
14. Demetri GD, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow WA, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies [abstract] 2010. In: Proceedings of the Gastrointestinal Cancers Symposium. American Society of Clinical Oncology: Alexandria, VA, USA, 2010
15. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, et al. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 20380-20385
16. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 2011; 108: 12372-12377
17. Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM, et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-Targeted dephosphorylation of CDC37. Mol Cell 2008; 31: 886-895
18. Smith JR, Workman P. Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009; 8: 362-372
19. Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, et al. Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine. Mol Cell 2012; 47: 434-443
20. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121
21. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008; 14: 240-248
22. Zhang T, Li Y, Yu Y, Zou P, Jiang Y, Sun D. Characterization of celastrol to inhibit HSP90 and CDC37 interaction. J Biol Chem 2009; 284: 35381-35389
23. Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA 2012; 17: 929-934.